DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Status
The amended claim set filed on 24 August 2026 is acknowledged. Claims 1-14 are currently pending. Of those, claim 7 is amended. There are no new claims and no claims are cancelled.
Election/Restrictions
Applicant’s election without traverse of Group I (claims 1-6 and 9) in the reply filed on 24 August 2026 is acknowledged. Claims 7-8 and 10-14 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 24 August 2026. Claims 1-6 and 9 will be examined on the merits herein.
Priority
The instant application is a 371 of application PCT/KR2023/003573 (filed 17 March 2023) and claims priority to foreign application KR 10-2022-0034234 (filed 18 March 2022). Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. However, because no certified translation of the foreign priority document was provided, the foreign priority claim has not been perfected. Therefore, for the purposes of searching the prior art, the effective filing date of instant claims 1-6 and 9 is 17 March 2023.
Information Disclosure Statement
The information disclosure statements (IDS) submitted on 13 September 2024, 10 October 2025, and 10 March 2026 are in compliance with the provisions of 37 CFR 1.97. Accordingly, each information disclosure statement is being considered by the examiner.
Claim Objections
Claims 1, 5, and 9 are objected to because of the following informalities: scientific names (e.g., Corynebacterium, Tribolium castaneum, and Corynebacterium glutamicum) should be italicized. Appropriate correction is required.
Claim Rejections - 35 USC § 103
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 1-3, 5-6, and 9 are rejected under 35 U.S.C. 103 as being unpatentable over Dietrich et al. (WO 2020/005834 A1; cited in IDS; herein “Dietrich”).
Regarding claims 1-2 and 5, Dietrich teaches recombinant host cells, including Corynebacterium glutamicum, capable of producing β-alanine comprising one or more heterologous nucleic acids that encode the β-alanine synthetic pathway (para. 7), wherein the β-alanine biosynthetic pathway includes a β-alanine-forming enzyme (para. 7), which is aspartate 1-decarboxylase, i.e., PanD (para. 10 and 116). Dietrich teaches that the PanD may be derived from T. castaneum (para. 119).
Regarding claim 3, Dietrich teaches that the T. castaneum PanD (TcPanD) has an amino acid sequence shown in SEQ ID NO: 38, which shares >99% sequence identity with instant SEQ ID NO: 27 (see Figure 1 for alignment below).
Regarding claim 6, Dietrich teaches that the recombinant host cells improve yields or productivity of β-alanine (para. 57).
However, Dietrich does not teach a composition comprising the Corynebacterium sp. microorganism producing β-alanine, as in claim 9.
Regarding claim 9, Dietrich teaches that their recombinant host cells can be cultured in order to produce β-alanine, i.e., a culture composition comprising the recombinant host cell capable of producing β-alanine (para. 213).
PNG
media_image1.png
705
636
media_image1.png
Greyscale
Figure 1: Alignment of instant SEQ ID NO: 27 (Qy) with Dietrich’s SEQ ID NO: 38 (Db).
Therefore, it would have been prima facie obvious, before the effective filing date of the claimed invention, to a person of ordinary skill in the art, to culture the Corynebacterium glutamicum expressing the TcPanD enzyme taught by Dietrich to produce β-alanine, thereby arriving at the invention of claims 1-3, 5-6, and 9. The person of ordinary skill in the art would have been motivated to make the modification in order for the C. glutamicum cells to produce the β-alanine and in order to collect the β-alanine. Therefore, the combination is also desirable (see MPEP 2144(II)). The person of ordinary skill in the art would have had a reasonable expectation of success because Dietrich teaches that any of their recombinant host cells for producing β-alanine may be cultured. Therefore, the combination leads to expected results because each element performs the same function as is does individually.
Additionally, KSR International Co. v. Teleflex Inc., 127 S. Ct. 1727, 1741 (2007), discloses that combining prior art elements according to known methods to yield predictable results, is obvious unless its application is beyond that person's skill. KSR International Co. v. Teleflex Inc., 127 S. Ct. 1727, 1741 (2007) also discloses that the combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results. In the instant case, all elements (i.e., Corynebacterium sp. producing β-alanine, T. castaneum PanD, Corynebacterium glutamicum, etc.) were known in the art. In addition, combining these elements yields a composition wherein each element merely performs the same function as it does separately; thus, the results of the combination would be recognized as predictable to one of ordinary skill in the art. Therefore, the claimed invention is prima facie obvious in view of the teachings of the prior art, absent any convincing evidence to the contrary.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-3, 5-6, and 9 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-3, 6-9, 11-14, and 16 of copending Application No. 18/885,239 (‘239). This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Regarding claims 1-3, the ‘239 claims teach a Corynebacterium sp. microorganism (‘239 claim 8) comprising the variant polypeptide having an activity of aspartate 1-decarboxylase (PanD), in which an amino acid corresponding the 139th residue of SEQ ID NO: 51 (which is identical to instant SEQ ID NO: 27; see Figure 2 for alignment below) (claims 1-3 and 6). Because the ‘239 claims SEQ ID NO: 51 is identical to the instant SEQ ID NO: 27, which is derived from a T. castaneum aspartate 1-decarboxylase, the ‘329 claims’ SEQ ID NO: 51 must also be derived from T. castaneum.
Regarding claim 5, the ‘239 claims teach that the Corynebacterium is Corynebacterium glutamicum (‘239 claim 9).
Regarding claim 9, the ‘239 claims teach a composition comprising a microorganism that contains the variant polypeptide having an activity of aspartate 1-decarboxylase (para. 11-14 and 16).
However, the ‘239 claims do not teach that the composition comprises a Corynebacterium comprising the variant polypeptide, as in instant claim 9.
Therefore, it would have been prima facie obvious, to a person of ordinary skill in the art, to use the Corynebacterium comprising the variant polypeptide having an aspartate 1-decarboxylase activity, as is taught in claim 8 of the ‘239 claims, in the composition and method comprising culturing the microorganism taught in claims 11-14 and 16 of the ‘239 claims, thereby arriving at the invention of instant claims 1-3, 5-6, and 9. The person of ordinary skill in the art would have been motivated to make the modification because the ‘239 claim 12 teaches that culturing the microorganism comprising the variant polypeptide having aspartate 1-decarboxylase activity allows for the recovery of β-alanine or β-alanine-derived compound. Therefore, the combination is also desirable (see MPEP 2144(II)). The person of ordinary skill in the art would have had a reasonable expectation of success because the ‘239 claims teach that their microorganism comprising the variant polypeptide having aspartate 1-decarboxylase activity may be cultured or used in the composition, so one would predict the same result using Corynebacterium sp. as the microorganism. Therefore, the combination leads to expected results because each element performs the same function as is does individually.
Additionally, KSR International Co. v. Teleflex Inc., 127 S. Ct. 1727, 1741 (2007), discloses that combining prior art elements according to known methods to yield predictable results, is obvious unless its application is beyond that person's skill. KSR International Co. v. Teleflex Inc., 127 S. Ct. 1727, 1741 (2007) also discloses that the combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results. In the instant case, all elements (i.e., Corynebacterium sp. producing β-alanine, T. castaneum PanD, Corynebacterium glutamicum, etc.) were known in the art. In addition, combining these elements yields a composition wherein each element merely performs the same function as it does separately; thus, the results of the combination would be recognized as predictable to one of ordinary skill in the art. Therefore, the claimed invention is prima facie obvious in view of the teachings of the prior art, absent any convincing evidence to the contrary.
PNG
media_image2.png
702
629
media_image2.png
Greyscale
Figure 2: Alignment of instant SEQ ID NO: 27 (Qy) with the ‘239 claims’ SEQ ID NO: 51 (Db).
Allowable Subject Matter
Claim 4 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Conclusion
No claim is allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to BAILEY M MORGAN whose telephone number is (703)756-5388. The examiner can normally be reached M-F 7:30-3:30 ET.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, SAMIRA JEAN-LOUIS can be reached at (571) 270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/BAILEY M MORGAN/Examiner, Art Unit 1645
/SAMIRA J JEAN-LOUIS/Supervisory Patent Examiner, Art Unit 1642